<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04146129</url>
  </required_header>
  <id_info>
    <org_study_id>CDX0159-01</org_study_id>
    <nct_id>NCT04146129</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study of CDX-0159</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Single Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CDX-0159 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celldex Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celldex Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to determine the safety of CDX-0159 in healthy subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CDX-0159 is a humanized monoclonal antibody that binds to a protein called KIT that is
      expressed on mast cells.

      This study will evaluate the safety, pharmacokinetics, and pharmacodynamics of CDX-0159 in
      healthy subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 29, 2019</start_date>
  <completion_date type="Actual">June 26, 2020</completion_date>
  <primary_completion_date type="Actual">April 6, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as assessed by CTCAE v5.0</measure>
    <time_frame>Day 1 to Day 43.</time_frame>
    <description>Safety of single, ascending doses of CDX-0159 as determined by percentage of participants with adverse events as assessed by CTCAE v5.0.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>CDX-0159</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive a single dose of CDX-0159</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects assigned to receive placebo will receive a single dose of normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CDX-0159</intervention_name>
    <description>Single dose of one of four dosages of CDX-0159</description>
    <arm_group_label>CDX-0159</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Single infusion of normal saline</description>
    <arm_group_label>Normal saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  An informed consent signed and dated by the subject.

          -  Healthy volunteer aged 18-55.

          -  In generally good health and without significant medical conditions based on physical
             exam, ECG, and laboratory test results.

          -  Body mass index (BMI) ≥ 18.5 kg/m2 to ≤ 30 kg/m2

          -  No medication other than mild analgesics, vitamins and mineral supplements or, oral
             contraceptives

          -  Both males and females of child bearing potential must agree to use a medically
             accepted contraceptive regimen during study and up to 150 days afterwards.

          -  Not a current smoker (or regular user of any nicotine containing product).

          -  Willing to follow all study rules

        Key Exclusion Criteria:

          -  Women who are pregnant or nursing

          -  History of anaphylaxis, food allergies, or allergies (chronic or seasonal) requiring
             prescription medication

          -  Autoimmune disorders requiring more than topical medication

          -  History of asthma requiring the use of inhaled medication within the past 5 years.

          -  Vaccination with live vaccines within 4 weeks prior to study drug administration
             (subjects must agree to avoid vaccination during the study).

          -  Positive urine test for alcohol and drugs of abuse.

        Other Protocol defined inclusion and exclusion criteria could apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Altasciences Clinical Kansas, Inc.</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 29, 2019</study_first_submitted>
  <study_first_submitted_qc>October 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2019</study_first_posted>
  <last_update_submitted>July 2, 2020</last_update_submitted>
  <last_update_submitted_qc>July 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CDX-0159</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

